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Few treatments for opiate addiction arouse as much controversy as naltrexone implants. 
Inserted under the skin, these block the effects of heroin for up to several months - for 
some, a magic bullet, for others, an unsafe and ethically dubious experiment. More 
evidence from Australia that the overdose death risk is less than with oral forms of the 
drug.
Summary At an Australian addiction treatment clinic the death rate of opiate-dependent 
patients treated with the heroin substitute buprenorphine between 2000 and 2007 was 
compared with those treated with implants of naltrexone which block the effects of heroin 
and allied drugs for up to several months. During this time 2518 patients were prescribed 
buprenorphine free of charge (though there were pharmacy charges) and 255 were 
implanted, mostly at their own expense. Records were matched with those of deaths 
recorded by the registrar of the relevant Australian state.
Main findings
Four naltrexone and 43 buprenorphine patients were known to have died. There were no 
deaths while a naltrexone implant was active but four among patients in whom the 
implant would no longer have been effective, resulting in an overall death rate of three 
deaths for every 1000 years the patients had been tracked. For buprenorphine the 
corresponding figure was 5.35, largely due to 40 deaths during times when the patients 
were not being prescribed the drug. Generally the death rate in each age band was lower 
for the naltrexone patients. All but one of the four naltrexone deaths occurred several 
months after the implant would no longer have been effective. 
The authors' conclusions
The major finding of the current study was that in terms of death rates, naltrexone 
implants compared favourably under most comparisons: with the same clinic's 
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experience of buprenorphine, with the Perth methadone programme, and even with 
Australian national population age-adjusted death figures. This was the case despite the 
fact that buprenorphine is a treatment widely recognised as safe and effective.
Another important finding was the utility of long-acting forms of naltrexone implants to 
promote treatment retention in a group of patients who tend to avoid traditional 
indefinite substitute prescribing programmes. 
 As with any abstinence-based treatment, relapse risking overdose due to 
lost tolerance to opiate-type drugs is a serious concern after naltrexone implants have 
lost their effectiveness. However, studies to date of naltrexone implants suggest these 
protect against overdose while they are active, and that in caseloads prepared to 
undertake these procedures, opiate overdose reductions can outlast the active period of 
the implants. The featured study is in line with this literature, which together suggests 
that implant and injectable long-acting forms of naltrexone are a major advance on oral 
naltrexone in safety and effectiveness in curbing illicit opiate use. However, the literature 
is small and methodologically weak. Reviewing it in 2010, the Australian government's 
National Health and Medical Research Council remained unconvinced of the safety or 
effectiveness of the implants and the long-term overdose risk after the treatment has 
ended. Their conclusion was that implants should "only be used in the context of a well 
conducted [randomised controlled trial] with sufficient sample size, appropriate duration 
of treatment and follow up, regular robust monitoring, provision of a comprehensive 
psychosocial treatment [programme], and with comparison to current best practice".
A criticism of trials to date is that they included highly selected patients. However, in this 
they may have reflected normal practice. Patients will only opt for such procedures if 
they are prepared (irreversibly in the case of depot injections) to commit to possibly 
weeks or months without the effects of heroin or other opiate-type drugs. From the 
control groups in naltrexone implant/depot studies, we know that even in these 
caseloads, treatment drop-out and relapse are common. Long-acting naltrexone helps 
these highly motivated patients sustain their resolve.
The clearest candidates for the treatment are patients who are motivated (perhaps 
because due to employment or other pressures, they have to) to return to a life without 
opiate-type drugs including prescribed substitutes, have the resources, stability and 
support to sustain this, are unlikely to simply use other drugs instead, but who when free 
to experience heroin and allied drugs, cannot resist using them, possibly reflected in their 
poor compliance with oral naltrexone regimens. The treatment may also be considered 
for unstable patients at very high risk of overdose, but who will not accept or do poorly in 
substitute prescribing programmes. Other candidates might include those unwilling or 
unable to accept daily supervised consumption if this is a requirement of being prescribed 
substitute medications.
As the featured study hints, it would not be justified to conclude from its findings that for 
any given patient or across a population, naltrexone implants which block heroin's effects 
are safer than buprenorphine which substitutes for heroin. Substitute prescribing, which 
'goes with the grain' of the patient's addiction, has mass appeal. Without it, many addicts 
would not enter treatment, especially if the step had to be as steep as from opiate use 
several times a day every day, to no opiate use (or at least, no effects) for months. 
Different kinds of patients are attracted to and suitable for these different treatments; 
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they might also have differed in their life expectancies even without treatment, and 
forced to accept the other option, might not have done as well as patients who chose it 
and/or were considered suitable.
In the featured study in particular, implant patients were the minority prepared not just to accept, but willing 
and able to pay for a procedure which would mean they could not experience opiate-type effects for up to 
several months. Additionally, buprenorphine patients spent very little time in treatment – just 14% of the time 
from when they started to the end of the study period. As detailed in another report on the same patients, at 
just 16 days the typical treatment duration on buprenorphine is suggestive of poor retention, and on average 
the patients were in and out of treatment three or four times. Retention was particularly and significantly worse 
among the buprenorphine patients who died. Counselling, was offered but not at the prescribing clinic, and few 
patients took up the offer. It seems likely that at this clinic the buprenorphine comparator was not implemented 
in a sufficiently supportive way to hold patients in treatment and exert the full protective effect. Set against 
this, long-acting naltrexone implants virtually ensured retention in an active pharmacotherapy for up to several 
months.
In the UK, neither implants nor depot injections of naltrexone have been licensed for 
medical use; they can still be (and have been; 1 2 3 4) used, but patient and doctor have 
to accept the added responsibility of a product which has not yet been shown to meet the 
safety and efficacy requirements involved in licensing.
Naltrexone implants and depot injections impede opiate-based pain relief. This is a greater problem with the 
irreversible long-acting naltrexone injection than with implants which can be removed. Possible adverse effects 
of naltrexone on liver function are also a concern based on early studies, but not one confirmed in several later 
studies.
This draft entry is currently subject to consultation and correction by the study authors and other experts. 
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